Cotinine as a biomarker of systemic nicotine exposure in spit tobacco users

被引:21
作者
Ebbert, JO
Dale, LC
Nirelli, LM
Schroeder, DR
Moyer, TP
Hurt, RD
机构
[1] Mayo Clin & Mayo Fdn, Dept Internal Med, Div Community Med, Rochester, MN 55905 USA
[2] Mayo Clin, Nicotine Dependence Ctr, Rochester, MN USA
[3] Mayo Clin, Sect Biostat, Dept Hlth Sci Res, Rochester, MN USA
[4] Mayo Clin, Div Biochem & Immunol, Dept Lab Med & Pathol, Rochester, MN USA
关键词
nicotine; cotinine; smokeless tobacco; chewing tobacco; biomarker;
D O I
10.1016/j.addbeh.2003.08.046
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Unlike cigarette smokers, spit tobacco (ST) users absorb a significant amount of nicotine through the gastrointestinal tract while swallowing tobacco juice. The majority of the absorbed nicotine is rapidly converted to cotinine during first-pass hepatic metabolism. This process potentially compromises the utility of cotinine as a biomarker for systemic nicotine exposure in ST users. To investigate this question, we correlated nicotine and cotinine concentrations with clinical measures of ST use in 68 daily ST users enrolled in a nonnicotine pharmacologic intervention trial. We found that a higher frequency of swallowing tobacco juice (P = .007) was an independent predictor of higher serum cotinine concentrations. Serum nicotine concentrations, on the other hand, were not correlated with a higher frequency of swallowing. In the absence of a reliable way to measure frequency of swallowing, we conclude that cotinine should not be used for guiding clinical decisions that depend upon a precise quantification of systemic nicotine exposure, such as tailored nicotine replacement therapy. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:349 / 355
页数:7
相关论文
共 14 条
[1]  
BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318
[2]   NICOTINE ABSORPTION AND CARDIOVASCULAR EFFECTS WITH SMOKELESS TOBACCO USE - COMPARISON WITH CIGARETTES AND NICOTINE GUM [J].
BENOWITZ, NL ;
PORCHET, H ;
SHEINER, L ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (01) :23-28
[3]   DAILY INTAKE OF NICOTINE DURING CIGARETTE-SMOKING [J].
BENOWITZ, NL ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (04) :499-504
[4]   DAILY USE OF SMOKELESS TOBACCO - SYSTEMIC EFFECTS [J].
BENOWITZ, NL ;
JACOB, P ;
YU, L .
ANNALS OF INTERNAL MEDICINE, 1989, 111 (02) :112-116
[5]   MEASURING DEPENDENCE IN SMOKELESS TOBACCO USERS [J].
BOYLE, RG ;
JENSEN, J ;
HATSUKAMI, DK ;
SEVERSON, HH .
ADDICTIVE BEHAVIORS, 1995, 20 (04) :443-450
[6]   THE PHARMACOKINETICS OF COTININE IN PLASMA AND SALIVA FROM NONSMOKING HEALTHY-VOLUNTEERS [J].
CURVALL, M ;
ELWIN, CE ;
KAZEMIVALA, E ;
WARHOLM, C ;
ENZELL, CR .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 38 (03) :281-287
[7]  
Dale Lowell C, 2002, Nicotine Tob Res, V4, P267, DOI 10.1080/14622200210153821
[8]   BLOOD COTININE LEVELS AS INDICATORS OF SMOKING TREATMENT OUTCOME [J].
HALL, SM ;
HERNING, RI ;
JONES, RT ;
BENOWITZ, NL ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (06) :810-814
[9]  
Hays JT, 2001, MAYO CLIN PROC, V76, P124
[10]   Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy [J].
Lawson, GM ;
Hurt, RD ;
Dale, LC ;
Offord, KP ;
Croghan, IT ;
Schroeder, DR ;
Jiang, NS .
JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (06) :502-509